AIT Therapeutics (OTCMKTS:AITB) and Motus GI (NASDAQ:MOTS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.
Valuation & Earnings
This table compares AIT Therapeutics and Motus GI’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AIT Therapeutics||N/A||N/A||-$18.04 million||($3.01)||-1.79|
|Motus GI||$40,000.00||1,592.66||-$22.26 million||($1.23)||-2.41|
Volatility & Risk
AIT Therapeutics has a beta of -0.31, meaning that its stock price is 131% less volatile than the S&P 500. Comparatively, Motus GI has a beta of 1.61, meaning that its stock price is 61% more volatile than the S&P 500.
This is a breakdown of recent ratings and recommmendations for AIT Therapeutics and Motus GI, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Motus GI has a consensus price target of $9.63, suggesting a potential upside of 224.07%. Given Motus GI’s higher probable upside, analysts plainly believe Motus GI is more favorable than AIT Therapeutics.
Institutional and Insider Ownership
35.3% of Motus GI shares are owned by institutional investors. 18.1% of Motus GI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This table compares AIT Therapeutics and Motus GI’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Motus GI beats AIT Therapeutics on 7 of the 11 factors compared between the two stocks.
About AIT Therapeutics
AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Garden City, New York.
About Motus GI
Motus GI Holdings, Inc. operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company is based in Fort Lauderdale, Florida.
Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.